Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Intravenous SelK2 for Prevention of Venous Thromboembolism After Total Knee Arthroplasty
2018-003122-88Phase 2Completed
- Sponsor
- Tetherex Pharmaceuticals
- Start
- Oct 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of SelK2 in venous thromboembolism (VTE), deep vein thrombosis (DVT) and pulmonary embolism (PE) (2 arms), sponsored by Tetherex Pharmaceuticals. Primary endpoint: Total venous thromboembolism incidence. Started Oct 2018; status: completed.
02
Drugs
SelK2
03
Conditions
venous thromboembolism (VTE)deep vein thrombosis (DVT)pulmonary embolism (PE)
Beyond the preview
Go deeper on 2018-003122-88.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003122-88.